ANI Pharmaceuticals Files 8-K

TL;DR

ANI Pharma filed an 8-K on Aug 7th, standard financial update.

AI Summary

ANI Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting other events and financial statements. The filing details the company's operations and financial condition, with no specific material events or transactions disclosed in the provided text.

Why It Matters

This filing provides routine updates and financial information for ANI Pharmaceuticals, Inc., which is important for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure without any immediate negative or positive material events.

Key Players & Entities

• ANI PHARMACEUTICALS, INC. (company) — Registrant
• August 7, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 58-2301143 (tax_id) — I.R.S. Employer Identification No.
• 210 Main Street West (address) — Principal executive offices
• Baudette, Minnesota (location) — Principal executive offices
• 56623 (zip_code) — Principal executive offices
• ( 218 ) 634-3500 (phone_number) — Registrant's telephone number
• BIOSANTE PHARMACEUTICALS INC (company) — Former Company Name
• BEN ABRAHAM TECHNOLOGIES INC (company) — Former Company Name

FAQ

Filing Documents

• dp216241_8k.htm (8-K) — 23KB
• dp216242_ex9901.htm (EX-99.1) — 16KB
• image_001.jpg (GRAPHIC) — 5KB
• 0000950103-24-011822.txt ( ) — 220KB
• anip-20240807.xsd (EX-101.SCH) — 3KB
• anip-20240807_lab.xml (EX-101.LAB) — 33KB
• anip-20240807_pre.xml (EX-101.PRE) — 22KB
• dp216241_8k_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On August 7, 2024, ANI Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its proposed private offering of Convertible Senior Notes due 2029 (the " Notes ") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this

01

Item 8.01. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company's common stock, if any, issuable upon conversion of the Notes. The Notes will not be registered under the Securities Act of 1933, as amended, or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended, and applicable state securities laws.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated August 7, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR